procaine has been researched along with Heart Disease, Ischemic in 19 studies
Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).
procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The reduction in hypothermia and ischaemia-induced reperfusion arrhythmias by the addition of sevoflurane to HTK solution may be related to the phosphorylation of Cx43 at serine 368." | 7.91 | Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368. ( Gao, H; Gao, J; Li, WC; Wang, ZJ, 2019) |
| "Regional myocardial ischemia was induced by occlusion of a diagonal branch of left anterior descending coronary artery of anesthetized cats." | 5.35 | Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2? ( Fu, LW; Longhurst, JC; Phan, A, 2008) |
| "The reduction in hypothermia and ischaemia-induced reperfusion arrhythmias by the addition of sevoflurane to HTK solution may be related to the phosphorylation of Cx43 at serine 368." | 3.91 | Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368. ( Gao, H; Gao, J; Li, WC; Wang, ZJ, 2019) |
| " In our study we compared myocardial protection in isolated coronary bypass with a short period of ischemia using low dosage HTK and cold crystalloid cardioplegia." | 2.71 | Low-dose histidine-tryptophan-ketoglutarate solution for myocardial protection. ( Akay, T; Arslan, A; Aslamaci, S; Gultekin, B; Ozkan, S; Sezgin, A; Tasdelen, A; Uguz, E, 2005) |
| "Regional myocardial ischemia was induced by occlusion of a diagonal branch of left anterior descending coronary artery of anesthetized cats." | 1.35 | Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2? ( Fu, LW; Longhurst, JC; Phan, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, J | 1 |
| Liu, X | 1 |
| Wang, M | 1 |
| Wang, X | 1 |
| Su, S | 1 |
| Li, WC | 1 |
| Gao, H | 1 |
| Gao, J | 1 |
| Wang, ZJ | 1 |
| Fu, LW | 1 |
| Phan, A | 1 |
| Longhurst, JC | 1 |
| Jacob, M | 1 |
| Paul, O | 1 |
| Mehringer, L | 1 |
| Chappell, D | 1 |
| Rehm, M | 1 |
| Welsch, U | 1 |
| Kaczmarek, I | 1 |
| Conzen, P | 1 |
| Becker, BF | 1 |
| Ikizler, M | 1 |
| Dernek, S | 1 |
| Sevin, B | 1 |
| Maxey, TS | 1 |
| Kural, T | 1 |
| Yotsumoto, G | 1 |
| Jeschkeit-Schubbert, S | 1 |
| Funcke, C | 1 |
| Kuhn-Régnier, F | 1 |
| Fischer, JH | 1 |
| Harlan, BJ | 1 |
| Ross, D | 1 |
| Macmanus, Q | 1 |
| Knight, R | 1 |
| Luber, J | 1 |
| Starr, A | 1 |
| Keembiyage, RD | 1 |
| Newland, HS | 1 |
| Lai, C | 1 |
| Wei, J | 1 |
| Chang, CY | 1 |
| Chuang, YC | 1 |
| Su, SH | 1 |
| Lee, KC | 1 |
| Tung, DY | 1 |
| Lee, SL | 1 |
| Lee, WC | 1 |
| Arslan, A | 1 |
| Sezgin, A | 1 |
| Gultekin, B | 1 |
| Ozkan, S | 1 |
| Akay, T | 1 |
| Uguz, E | 1 |
| Tasdelen, A | 1 |
| Aslamaci, S | 1 |
| Kossitsky, GI | 1 |
| Kalmykov, VW | 1 |
| Bolotova, MF | 1 |
| Mühlfeld, C | 1 |
| Urru, M | 1 |
| Rümelin, R | 1 |
| Mirzaie, M | 1 |
| Schöndube, F | 1 |
| Richter, J | 5 |
| Dörge, H | 1 |
| Kober, IM | 1 |
| Obermayr, RP | 1 |
| Spieckermann, PG | 1 |
| Schmiedl, A | 4 |
| Schnabel, PA | 3 |
| Hachida, M | 1 |
| Lu, H | 1 |
| Ohkado, A | 1 |
| Hoshi, H | 1 |
| Gu, H | 1 |
| Nakanishi, T | 1 |
| Koyanagi, H | 1 |
| Gerber, SH | 1 |
| Heyer, C | 1 |
| Krüger, C | 1 |
| Hagl, S | 1 |
| Kübler, W | 1 |
| Haass, M | 1 |
| Stoletzki, S | 1 |
| Kausch Blecken von Schmeling, H | 1 |
| Marten, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial[NCT01681095] | Phase 2 | 110 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with all-cause mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
CK-MB measured 24 hours post-operatively (NCT01681095)
Timeframe: 24 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 20 |
| Cold Blood Cardioplegia | 24 |
CK-MB measured 48 hours post-operatively (NCT01681095)
Timeframe: 48 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 6.0 |
| Cold Blood Cardioplegia | 7.8 |
CK-MB measured pre-operatively (NCT01681095)
Timeframe: pre-operative
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 1.9 |
| Cold Blood Cardioplegia | 2.6 |
Number of participants with new or worsening of cardiac dysrhythmias (NCT01681095)
Timeframe: up to 36 hrs post surgery
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 24 |
| Cold Blood Cardioplegia | 30 |
Troponin-I measured 24 hours post-operative (NCT01681095)
Timeframe: 24 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 5.7 |
| Cold Blood Cardioplegia | 7.8 |
Troponin-I measured 48 hours post-operative (NCT01681095)
Timeframe: 48 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 3.0 |
| Cold Blood Cardioplegia | 4.8 |
Troponin-I measured pre-operatively (NCT01681095)
Timeframe: pre-operatively
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | .03 |
| Cold Blood Cardioplegia | .03 |
Number of participants with cardiovascular-related mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
Creatine phosphokinase MB isoenzyme (CK-MB) difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery
| Intervention | ng/mL (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 18.8 |
| Cold Blood Cardioplegia | 22.2 |
Troponin I values, difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery
| Intervention | ng/mL (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 9.65 |
| Cold Blood Cardioplegia | 10.15 |
LV ejection fraction by TTE, difference from baseline at 24 hours post surgery (NCT01681095)
Timeframe: Baseline and 24 hours post surgery
| Intervention | % LV volume (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | -0.06 |
| Cold Blood Cardioplegia | 1.9 |
Total time in minutes on any vasopressor or inotropic agent, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | minutes (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 340 |
| Cold Blood Cardioplegia | 582 |
Duration of stay in ICU, from ICU admission to ICU discharge (NCT01681095)
Timeframe: up to 100 days after admission
| Intervention | days (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 3 |
| Cold Blood Cardioplegia | 3 |
Number or participants fulfilling at least two of the following 3 criteria: (1) CK-MB of 100 ug/L or more and/or troponin-I of 3.0 ug/L or more, (2) appearance of new postoperative Q waves on the EKG of more than 0.03 seconds, and (3) a new hypokinetic or akinetic area in the left or right ventricle by echocardiography. (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
Number of patients receiving vasopressor or inotropic infusion for greater than 20 minutes in the operating room, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine. (NCT01681095)
Timeframe: during operative procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 47 |
| Cold Blood Cardioplegia | 43 |
time in hours from intubation to extubation, with intervening transport to the cardiac critical care unit. (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | hours (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 10.5 |
| Cold Blood Cardioplegia | 11.4 |
1 trial available for procaine and Heart Disease, Ischemic
| Article | Year |
|---|---|
Low-dose histidine-tryptophan-ketoglutarate solution for myocardial protection.
Topics: Adult; Aged; Cardioplegic Solutions; Coronary Artery Bypass; Coronary Disease; Creatine Kinase; Fema | 2005 |
18 other studies available for procaine and Heart Disease, Ischemic
| Article | Year |
|---|---|
Reduction of Cold Ischemic Injury with the Addition of Compound Glycyrrhizin in HTK Solution in a Mouse Heart Transplantation Model.
Topics: Animals; Anti-Inflammatory Agents; Cold Ischemia; Drug Evaluation, Preclinical; Glucose; Glycyrrhizi | 2020 |
Antiarrhythmic effect of sevoflurane as an additive to HTK solution on reperfusion arrhythmias induced by hypothermia and ischaemia is associated with the phosphorylation of connexin 43 at serine 368.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Connexin 43; Disease Models, Animal; Gap Junc | 2019 |
Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2?
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Anesthetics, Local; Animals; Cat | 2008 |
Albumin augmentation improves condition of guinea pig hearts after 4 hr of cold ischemia.
Topics: Animals; Cardiac Output; Cell Adhesion; Coronary Vessels; Edema; Endothelium, Vascular; Glucose; Gui | 2009 |
Improved myocardial function with the addition of pinacidil to custadiol.
Topics: Animals; Blood Pressure; Coronary Circulation; Creatine Kinase; Glucose; Heart; Hypothermia, Induced | 2002 |
Total recovery of heart grafts of non-heart-beating donors after 3 hours of hypothermic coronary oxygen persufflation preservation in an orthotopic pig transplantation model.
Topics: Animals; Diacetyl; Glucose; Heart Arrest; Heart Transplantation; Heart-Lung Machine; Hypothermia, In | 2003 |
Cardioplegic solutions for myocardial preservation: analysis of hypothermic arrest, potassium arrest, and procaine arrest.
Topics: Animals; Cardioplegic Solutions; Coronary Circulation; Heart; Heart Arrest, Induced; Hypothermia, In | 1978 |
Tachycardia and myocardial ischaemia following subconjunctival injection of mydricaine (number 02) for vitrectomy procedure.
Topics: Aged; Anesthetics, Local; Atropine; Conjunctiva; Drug Therapy, Combination; Electrocardiography; Epi | 2005 |
Successful heart transplantation after 13 hours of donor heart ischemia with the use of HTK solution: a case report.
Topics: Adolescent; Glucose; Heart; Heart Transplantation; Humans; Male; Mannitol; Myocardial Ischemia; Pota | 2005 |
Changes in brain circulation in acute coronary insufficiency.
Topics: Animals; Cerebrovascular Circulation; Constriction, Pathologic; Coronary Disease; Coronary Vessels; | 1977 |
Myocardial ischemia tolerance in the newborn rat involving opioid receptors and mitochondrial K+ channels.
Topics: Animals; Decanoic Acids; Glucose; Hydroxy Acids; Mannitol; Mitochondria; Myocardial Ischemia; Myocyt | 2006 |
How beneficial is the reduction of edema formation by polyethylene glycol during cardioplegic arrest?
Topics: Animals; Blood Pressure; Cardioplegic Solutions; Coronary Circulation; Edema; Glucose; Heart; Heart | 1996 |
Cellular edema and alterations in metabolite content in the ischemic and reperfused canine heart following different forms of cardiac arrest.
Topics: Animals; Aorta; Bicarbonates; Calcium Chloride; Cardiomyopathies; Cardioplegic Solutions; Constricti | 1996 |
Effectiveness of ischemic preconditioning on long-term myocardial preservation.
Topics: Animals; Calcium; Cardioplegic Solutions; Coronary Circulation; Creatine Kinase; Glucose; Heart; In | 1998 |
Influence of Bretschneider's cardioplegia on norepinephrine release from isolated perfused guinea-pig hearts.
Topics: Adrenergic Uptake Inhibitors; Amiloride; Animals; Desipramine; Dose-Response Relationship, Drug; Fev | 1999 |
Intercalated clear cells or pale cells in the sinus node of canine hearts? An ultrastructural study.
Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Dogs; Female; Glucose; Heart; Heart | 2000 |
Swelling of capillary endothelial cells and cardiomyocytes in the ischaemic myocardium of artificially arrested canine hearts.
Topics: Adenosine; Allopurinol; Animals; Bicarbonates; Calcium Chloride; Capillaries; Cardioplegic Solutions | 2001 |
Different preservation of myocardial capillary endothelial cells and cardiomyocytes during and after cardioplegic ischemia (25 degrees C) of canine hearts.
Topics: Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Dogs; Endothelium, Vascular; Female | 2002 |